Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481132 | 1.00 | FFAR4 (0.49) | FFAR4FFAR1PPARACYSLTR2CYSLTR1 | |
| SCHEMBL1481717 | 0.94 | PPARA (0.52) | FFAR4FFAR1PPARACYSLTR2CYSLTR1 | |
| SCHEMBL1481721 | 0.94 | PPARA (0.52) | FFAR4FFAR1PPARACYSLTR2CYSLTR1 | |
| SCHEMBL1480406 | 0.92 | LTB4R (0.41) | FFAR4FFAR1PPARALTB4R | |
| SCHEMBL1480408 | 0.92 | LTB4R (0.41) | FFAR4FFAR1PPARALTB4R | |
| SCHEMBL1481360 | 0.91 | PPARA (0.42) | FFAR4FFAR1PPARACYSLTR2CYSLTR1 | |
| SCHEMBL1481491 | 0.91 | PPARA (0.42) | FFAR4FFAR1PPARACYSLTR2CYSLTR1 | |
| SCHEMBL1481604 | 0.88 | CASP3 (0.50) | FFAR4FFAR1PPARACYSLTR2CYSLTR1 | |
| SCHEMBL1481600 | 0.88 | CASP3 (0.50) | FFAR4FFAR1PPARACYSLTR2CYSLTR1 | |
| SCHEMBL1481817 | 0.87 | AGER (0.49) | FFAR4FFAR1PPARACYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | FFAR4 2604/4885FFAR1 1810/4885PPARA 2236/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | FFAR4 2604/4885FFAR1 1810/4885PPARA 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.